Close Menu

NEW YORK – Liquid biopsy firm Biocept has completed a 1-for-10 reverse stock split to regain compliance with the Nasdaq $1.00 minimum bid price requirement. As a result of the split, effective with the open of the market on Tuesday, the firm's common stock is now trading on a split-adjusted basis.

Authorization for the reverse split was approved by the company's stockholders at Biocept's 2020 annual shareholder meeting, although the vote was delayed several times due to an insufficient number of ballots in favor.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.